MX2013003589A - Derivados de 4-(metilaminofenoxi)piridin-3-il-benzamida para tratar cancer. - Google Patents

Derivados de 4-(metilaminofenoxi)piridin-3-il-benzamida para tratar cancer.

Info

Publication number
MX2013003589A
MX2013003589A MX2013003589A MX2013003589A MX2013003589A MX 2013003589 A MX2013003589 A MX 2013003589A MX 2013003589 A MX2013003589 A MX 2013003589A MX 2013003589 A MX2013003589 A MX 2013003589A MX 2013003589 A MX2013003589 A MX 2013003589A
Authority
MX
Mexico
Prior art keywords
methylaminophenoxy
pyrdin
treating cancer
benzamide derivatives
lower alkyl
Prior art date
Application number
MX2013003589A
Other languages
English (en)
Inventor
Makoto Sakamoto
Takashi Nakagawa
Takumi Sumida
Yutaka Kojima
Kazuya Yamaguchi
Yuki Terauchi
Masamichi Shirakura
Yasuo Harada
Original Assignee
Otsuka Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceuticals Co Ltd filed Critical Otsuka Pharmaceuticals Co Ltd
Publication of MX2013003589A publication Critical patent/MX2013003589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un nuevo compuesto que tiene un excelente efecto antitumoral, excelente estabilidad y excelente estabilidad metabólica. El compuesto de la presente invención se representa por la siguiente fórmula general (1) donde R1 representa un átomo de halógeno, un grupo arilo, un grupo ariloxi o un grupo alquilo inferior opcionalmente sustituido con uno o más átomos de halógeno; R2 representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo inferior o un grupo alcoxi inferior, y m representa un número entero de 1 a 3; con la condición que cuando m represente 2 o 3, las R1 sean las mismas o diferentes.
MX2013003589A 2010-10-04 2011-10-03 Derivados de 4-(metilaminofenoxi)piridin-3-il-benzamida para tratar cancer. MX2013003589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38939310P 2010-10-04 2010-10-04
PCT/JP2011/073165 WO2012046825A1 (en) 2010-10-04 2011-10-03 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer

Publications (1)

Publication Number Publication Date
MX2013003589A true MX2013003589A (es) 2013-06-24

Family

ID=44872549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003589A MX2013003589A (es) 2010-10-04 2011-10-03 Derivados de 4-(metilaminofenoxi)piridin-3-il-benzamida para tratar cancer.

Country Status (29)

Country Link
US (7) US8946437B2 (es)
EP (1) EP2624833B1 (es)
JP (1) JP5715690B2 (es)
KR (1) KR101797797B1 (es)
CN (1) CN103189061B (es)
AR (1) AR083287A1 (es)
AU (1) AU2011313236B2 (es)
BR (1) BR112013007841B1 (es)
CA (1) CA2813153C (es)
CO (1) CO6660459A2 (es)
DK (1) DK2624833T3 (es)
EA (1) EA021627B1 (es)
ES (1) ES2526574T3 (es)
HK (1) HK1187540A1 (es)
HR (1) HRP20141237T1 (es)
IL (1) IL225520A (es)
MX (1) MX2013003589A (es)
MY (1) MY157563A (es)
NZ (1) NZ609151A (es)
PL (1) PL2624833T3 (es)
PT (1) PT2624833E (es)
RS (1) RS53749B1 (es)
SG (1) SG189146A1 (es)
SI (1) SI2624833T1 (es)
SM (1) SMT201500056B (es)
TW (1) TWI526431B (es)
UA (1) UA110037C2 (es)
WO (1) WO2012046825A1 (es)
ZA (1) ZA201302332B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2813153C (en) * 2010-10-04 2019-01-15 Otsuka Pharmaceutical Co., Ltd. 4-(methylaminophenoxy) pyrdin-3-yl-benzamide derivatives for treating cancer
JP6066806B2 (ja) * 2012-04-03 2017-01-25 大塚製薬株式会社 医薬
WO2020196665A1 (en) 2019-03-25 2020-10-01 Otsuka Pharmaceutical Co., Ltd. Antitumor composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
RU2416608C2 (ru) 2004-08-06 2011-04-20 Оцука Фармасьютикал Ко., Лтд. Ароматическое соединение
MY146514A (en) 2005-12-05 2012-08-15 Otsuka Pharma Co Ltd Diarylether derivatives as antitumor agents
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
CA2813153C (en) * 2010-10-04 2019-01-15 Otsuka Pharmaceutical Co., Ltd. 4-(methylaminophenoxy) pyrdin-3-yl-benzamide derivatives for treating cancer
WO2020196665A1 (en) * 2019-03-25 2020-10-01 Otsuka Pharmaceutical Co., Ltd. Antitumor composition

Also Published As

Publication number Publication date
WO2012046825A1 (en) 2012-04-12
HK1187540A1 (en) 2014-04-11
KR101797797B1 (ko) 2017-11-14
US20130267565A1 (en) 2013-10-10
ES2526574T3 (es) 2015-01-13
CO6660459A2 (es) 2013-04-30
CA2813153A1 (en) 2012-04-12
IL225520A0 (en) 2013-06-27
TW201307289A (zh) 2013-02-16
US20170298023A1 (en) 2017-10-19
JP5715690B2 (ja) 2015-05-13
IL225520A (en) 2016-05-31
SI2624833T1 (sl) 2015-03-31
AR083287A1 (es) 2013-02-13
US20180265471A1 (en) 2018-09-20
EA021627B1 (ru) 2015-07-30
US8946437B2 (en) 2015-02-03
AU2011313236A1 (en) 2013-04-18
EA201390323A1 (ru) 2013-09-30
US20210017134A1 (en) 2021-01-21
BR112013007841A2 (pt) 2016-06-07
SG189146A1 (en) 2013-05-31
ZA201302332B (en) 2014-07-30
JP2013538785A (ja) 2013-10-17
EP2624833A1 (en) 2013-08-14
PT2624833E (pt) 2014-12-26
UA110037C2 (uk) 2015-11-10
RS53749B1 (en) 2015-06-30
MY157563A (en) 2016-06-30
US20200031773A1 (en) 2020-01-30
US20230139808A1 (en) 2023-05-04
HRP20141237T1 (hr) 2015-02-13
CA2813153C (en) 2019-01-15
CN103189061A (zh) 2013-07-03
NZ609151A (en) 2015-01-30
DK2624833T3 (en) 2015-01-05
US20150105432A1 (en) 2015-04-16
EP2624833B1 (en) 2014-12-10
PL2624833T3 (pl) 2015-05-29
KR20130121826A (ko) 2013-11-06
SMT201500056B (it) 2015-05-05
TWI526431B (zh) 2016-03-21
CN103189061B (zh) 2015-09-02
AU2011313236B2 (en) 2016-05-19
BR112013007841B1 (pt) 2020-03-03

Similar Documents

Publication Publication Date Title
CY1120066T1 (el) Ενωση κινολονης
JO3509B1 (ar) معدلات p2x7
IN2014CN02838A (es)
MY188913A (en) Cyclic amine compound and acaricide
MX2010012199A (es) Compuesto de cromeno.
MX337714B (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
IN2014CN03976A (es)
MY161134A (en) Piperazine compound having a pgds inhibitory effect
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
IN2014DN10723A (es)
MX2013006811A (es) Compuestos, composiciones y articulos fotocromaticos.
CY1117026T1 (el) Ετεροκυκλικες ενωσεις για αντιμετωπιση ή προληψη διαταραχων που προκαλουνται απο μειωμενη νευροδιαβιβαση σεροτονινης, νορεπινεφρινης ή ντοπαμινης
PH12014502663B1 (en) Aromatic heterocyclic derivative and pharmaceutical
MY160253A (en) Prophylactic or ameliorating agent for pigmentation
MX369470B (es) Medios y método para el tratamiento de tumores sólidos.
MY157563A (en) 4- (methylaminophenoxy) pyrdin-3-yl-benzamide derivatives for treating cancer
EP2612848A4 (en) CYCLIC AMIDE DERIVATIVE
MY170131A (en) Tracers and method of marking hydrocarbon liquids
IN2014DN08653A (es)
SE1100784A1 (sv) Ny fosfatförening
MX348867B (es) Compuestos quimicos.
IN2015DN02514A (es)
IN2012DN01251A (es)
SA515360302B1 (ar) مركبات رباعي أكسا ثنائي فوسفا سبيرو
MX2013005179A (es) Derivado de pirazino[2,3-d]isoxazol.

Legal Events

Date Code Title Description
FG Grant or registration